Global Down Syndrome Market Overview, Epidemiology and Market


Dublin, December 23, 2020 (GLOBE NEWSWIRE) – The ‘Down Syndrome – Market Overview, Epidemiology and Forecast – 2030’ drug pipelines have been added to offer.

This report “Down Syndrome (DS) – Market Insights, Epidemiology, and Market Forecast – 2030” provides an in-depth understanding of the historical and predicted epidemiology and trends of the Down Syndrome (DS) market in United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Down Syndrome (DS) Market report provides the current treatment practices, emerging drugs, individual therapies market share, and the current and forecasted Down Syndrome market size from 2017 to 2030, segmented by seven main markets. The report also covers the current Down Syndrome (DS) treatment practice / algorithm, market drivers, market barriers, and unmet medical need to organize the best opportunities and assess the potential of the underlying market. .

Diagnosis and treatment of Down syndrome (SD)

It covers the details of conventional and current medical therapies and diagnostics available in the Down Syndrome (DS) market to treat the disease. It also provides the processing guidelines and algorithms by country in the United States, Europe and Japan.

The Down Syndrome (DS) Market report gives an in-depth understanding of the Down Syndrome symptoms by including such details as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Down syndrome symptom treatment algorithms and treatment guidelines for Down syndrome symptoms in the United States, Europe, and Japan.

Down Syndrome (SD) Epidemiology

The Down Syndrome Symptom Epidemiology division provides information on the historical and current patient pool as well as the forecast trend for all seven major countries. It helps to recognize the causes of current and forecast trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the pool of patients diagnosed and their trends as well as the assumptions made.

Main conclusions

The disease epidemiology covered in the report provides the historical and predicted epidemiology of Down syndrome (DS) segmented as the total number of cases diagnosed with Down syndrome, the prevalent population diagnosed with specific type of Down syndrome, the sex-specific prevalent population diagnosed with Down syndrome, prevalent population diagnosed by age with Down syndrome, and prevalent population diagnosed with Down syndrome by clinical manifestation. The report includes the prevalent scenario of Down syndrome symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain and United Kingdom) and Japan from 2017 to 2030.

National epidemiology of Down syndrome (SD)

The epidemiology segment also provides data and epidemiological results on Down syndrome in the United States, the EU5 (Germany, France, Italy, Spain and the United Kingdom) and Japan.

The total population diagnosed prevalent with Down syndrome (DS) in 7MM countries was estimated at 699,750 cases in 2017.

Down Syndrome (DS) Drugs Chapters

The Drugs chapter segment of the Down Syndrome (DS) report contains the detailed analysis of the marketed Down syndrome drugs and the late stage pipeline drugs (Phase-III and Phase-II). It also helps to understand the details of the Down syndrome (DS) clinical trial, expressive pharmacological action, agreements and collaborations, details of approval and patents, advantages and disadvantages of each. drug included, as well as the latest news and press releases.

Emerging Drugs for Down Syndrome (SD)

ANVS-401 (Annovis Bio)
Annovis Bio is developing ANVS-401 as a combination therapy approach to inhibit the translation of several neurotoxic proteins such as APP / A ?, tau / phospho-tau and? -Synuclein. ANVS-401 can improve axonal transport, increase synaptic transmission, prevent inflammation, and restore cascading events by reducing APP, tau, and alpha-synuclein levels and maintaining nerve cell health. . The company plans to obtain human data for AD in Down syndrome than in the normal AD population. Now he plans to conduct a pivotal Phase III study in AD-DS rather than AD.

Down’s syndrome market outlook

The Down’s Syndrome (DS) Market Outlook report helps to understand in detail the historical, current and forecast trends of the Down’s syndrome (DS) market by analyzing the impact of current therapies in the market, unmet need , drivers and barriers, and the demand for better technology.

This segment gives a complete detail of the Down syndrome (DS) market trend of each marketed drug and advanced stage pipeline therapy by assessing their impact based on annual cost of treatment, inclusion and exclusion criteria. , mechanism of action, rate of compliance, growing market needs, increase in the number of patients, patient segment covered, year of planned launch, competition with other therapies, brand value, their impact on the market and viewpoint of key opinion leaders. The calculated market data is presented with relevant tables and charts to give a clear view of the market at first glance.

According to the publisher, the 7MM Down syndrome (DS) market is expected to evolve during the 2017-2030 study period.

The current Down syndrome market is dominated by the use of supportive therapies depending on the manifestations such as anxiolytics, anticonvulsants, antidepressants, antihypertensives, antipsychotics, antispasmodics, cholesterol lowering drugs, cholinesterase inhibitors, linked to GERD. drugs (eg, proton pump inhibitors), hormones (other than thyroid hormones and others.

Main conclusions

This section includes an overview of the Down syndrome (DS) in 7MM market. The trisomy 21 market size in the top seven markets was US $ 662.9 million in 2017.

Down Syndrome (SD) Taking medication

This section focuses on the absorption rate of potential drugs recently launched or expected to be marketed during the study period 2017-2030. The analysis covers market uptake of Down syndrome by drugs, uptake by patients by therapies, and sales of each drug.

This helps to understand which drugs are most rapidly absorbed, the reasons for the maximum use of new drugs, and allows drugs to be compared based on market share and size, which again will be useful for studying the important factors in market adoption and in making financial and regulatory decisions.

Down Syndrome (DS) pipeline development activities

The report provides information on different therapeutic candidates in phase II and phase III. It also analyzes the key players in Down’s syndrome involved in the development of targeted therapies.

Some of the major players and their carpet candidates expected to launch during the forecast period (2020-2030) include Annovis Bio (ANVS-401), AC Immune (ACI-24), Alzheon (ALZ-801), Balance Therapeutics (BTD -001), Aelis Farma (AEF0217) and others.

Pipeline development activities

The report covers detailed information on collaborations, mergers and acquisitions, licensing and patent details for emerging therapies for Down syndrome (DS).

Reimbursement Scenario in Down Syndrome (SD)

Many children with SD are included as secondary subscribers under their parents’ employer-sponsored health care plans. In this case, families with higher deductibles might end up having more out-of-pocket expenses simply because children with DS typically have more outpatient appointments than their neurotypically developing peers. Children and adolescents with non-mosaic DS are also automatically eligible for Medicaid as primary or secondary health insurance; however, co-payments may vary based on parental income and different state regulations. For example, a low-income single-parent household might have all of the direct health expenses of a child with SD covered by Medicaid; whereas a middle-income household may have a monthly co-payment for the same Medicaid coverage.

Competitive intelligence analysis

The publisher performs competitive and market analysis of Down syndrome (DS) market using various competitive intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG matrix, market entry strategies , etc. The inclusion of the analysis is entirely dependent on the availability of data.

Companies mentioned

  • AC Immune
  • Annovis Bio
  • Alzheon
  • OPKO Health, Inc.
  • Aelis Farma

For more information on this Drug Pipeline Report, visit

Research and Markets also offers personalized research services providing targeted, comprehensive and personalized research.


Comments are closed.